← boardnext 2027-02
ENLV
Enlivex Therapeutics Ltd.distress 7/10 · high distress / dilution risk$4.32-6%today-84% from 52w high
Immunology / Inflammation 1Pain 1
Lead: Primary Knee Osteoarthritis
Revenue
pre-revenue
Liquidity
$2M
Runway
0.2 yrs
Shares 1y
0%
Price & events
-72.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-5.8%
1D
-9.1%
1W
-52.9%
1M
-68.2%
3M
-73.3%
6M
-75.4%
1Y
-80.0%
2Y
-96.1%
5Y
-97.0%
All
Overview
- Market Cap
- $1.03B
- Enterprise Value
- $1.03B
- Volume
- 7.70K
- 52 Week Range
- $4.32 – $27.30
- Total Shares
- 237.38M
- Float Shares
- 3.85M
- Short %
- 0.63%
- % Held by Insiders
- 81.40%
- % Held by Institutions
- 1.44%
- RVOL
- 0.14x
- Beta
- 1.52
Pipeline stages · 1 programs
Allocetra
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 1 upcoming
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-04-07HC Wainwright & Co.Buy
- 2026-01-12HC Wainwright & Co.Buy
- 2025-11-24D. Boral CapitalBuy → Hold
- 2025-10-29D. Boral CapitalBuy
- 2025-09-26D. Boral CapitalBuy
- 2025-09-12D. Boral CapitalBuy
Competitors — Primary Knee Osteoarthritis
- none identified
Recent news
- 2026-07-20Enlivex Ltd. (ENLV) Rallies 1.71% – Testing Key Resistance at $5.0 - Fibonacci Extension - dars.gov.et
- 2026-07-20Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion - The Manila Times
- 2026-07-20Enlivex (Nasdaq: ENLV) details $1.1B RAIN token holdings and NAV - Stock Titan
- 2026-07-20Enlivex’s Net Asset Value Per Share Was $66.16 on July 18 - Stock Titan
- 2026-07-13Enlivex (ENLV) Receives RMAT Designation for Knee Osteoarthritis Treatment - GuruFocus
- 2026-07-13FDA grants regenerative medicine designation to Enlivex therapy By Investing.com - Investing.com Nigeria
- 2026-07-13Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis - The Manila Times
- 2026-07-13FDA grants regenerative medicine designation to Enlivex therapy By Investing.com - Investing.com Canada
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.